GÉTICA 2021

27 [ F I T C á n c e r - 7 ] Financiación: Grupo Oncológico para el Tratamien- to y el Estudio de Linfomas (GOTEL) yy IIT-Celgene. BIBLIOGRAFÍA 1. Giovannucci E. The epidemiology of vitamin D and can- cer incidence and mortality: a review. Cancer Causes Control 2005;16(2):83-95. 2. Bittenbring JT, Neumann F, Altmann B, et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxi- city and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol 2014;32(29):3242-8. 3. Hohaus S, Tisi MC, Bellesi S, et al. Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. Can- cer Med 2018;7(1):270-81. 4. Brosseau C, Dousset C, Touzeau C, et al. Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK. Cell Death Dis 2014;5:e1389. Conclusiones: La baja concentración de vita- mina D en los pacientes permitió comprobar su inmunosupresión. La terapia experimental R2- GDP ha demostrado ser una alternativa eficaz en segunda línea acorde a la SG en DLBCL, donde además podría tener un importante papel la vi- tamina D. Estos resultados se ven apoyados por una disminución de las MDSCs en los pacientes que no presentan déficit de vitamina D. Acorde a nuestros resultados, podría conside- rarse investigar la adición de vitamina D en tra- tamientos que combinen lenalidomida y ritu- ximab con intención inmunomoduladora para mejorar los resultados clínicos en los linfomas de células B. CC06. RETHINKING PROGNOSTIC FACTORS IN LOCALLY ADVANCED ORMETASTATIC UROTHELIAL CARCINOMA IN THE IMMUNE CHECKPOINT BLOCKADE ERA: A MULTICENTER RETROSPECTIVE STUDY Ruiz Bañobre, Juan 1 ; Molina Díaz, Áurea 2 ; Fernández Calvo, Ovidio 3 ; Fernández Núñez, Natalia 4 ; Medina Colmenero, Ana 5 ; Santomé, Lucía 6 ; Lázaro Quintela, Martín 7 ; Mateos González, María 1 ; García Cid, Noelia 3 ; López López, Rafael 1 ; Vázquez, Sergio 4 ; Anido Herranz, Urbano 1 1 Medical Oncology Department & Translational Medical Oncology Group (Oncomet). Hospital Clínico Universitario de Santiago de Compostela. Universidad de Santiago de Compostela (USC). Santiago de Compostela, A Coruña. 2 Medical Oncology Department. Complejo Hospitalario Universitario de A Coruña. A Coruña. 3 Medical Oncology Department. Complejo Hospitalario Universitario de Ourense. Ourense. 4 Medical Oncology Department. Hospital Universitario Lucus Augusti. Lugo. 5 Medical Oncology Department. Centro Oncológico de Galicia. A Coruña. 6 Medical Oncology Department. Hospital Povisa. Vigo. 7 Medical Oncology Department. Complejo Hospitalario Universitario de Vigo. Vigo (L)1 monotherapy and to identify pretreat- ment factors influencing therapy outcomes. In addition, an independent prognostic mod- el for overall survival (OS) was developed and internally validated. Patients and methods: We conducted a multicenter retrospective study involving 119 previously treated or untreated mUC Background: Few studies have investigated the safety and efficacy of anti-PD-(L)1 antibod- ies in metastatic urothelial carcinoma (mUC) in daily clinical practice. Knowledge about the influence of baseline clinical and analytical factors on therapy outcomes is scarce. Objectives: The objectives of this study were to confirm the safety and efficacy of anti-PD-